Risk of complications from bone metastases in breast cancer: implications for management

被引:125
|
作者
Plunkett, TA [1 ]
Smith, P [1 ]
Rubens, RD [1 ]
机构
[1] Guys Hosp, Acad Oncol Unit, London SE1 9RT, England
关键词
breast cancer; bone metastases; radiotherapy; bisphosphonates;
D O I
10.1016/S0959-8049(99)00331-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective analysis of 859 patients who developed bone metastases from breast cancer between 1975 and 1991 was performed in order to identify factors that predict for complications from skeletal disease. The patients were divided into four groups based on the sites of disease at diagnosis of skeletal metastases: bone disease only; bone and soft tissue disease: bone and pleuro-pulmonary disease. bone and liver disease. Patients with metastatic disease confined to the skeleton were most likely to develop a pathological fracture. The time to long bone fracture was similar for all groups, but the least number of such fractures occurred in patients with bone and liver metastases since their survival was shortest (median: 5.5 months; P<0.001). patients with bone metastases only were most likely to require radiotherapy to painful osseous deposits (P = 0.0001) and most rapidly developed spinal cord compression (P = 0.01. data not shown). The results suggest that patients with disease confined to the skeleton at the diagnosis of bone metastases are most likely to develop skeletal-related complications from advanced breast cancer. Such patients may benefit most from treatment with bisphosphonates. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:476 / 482
页数:7
相关论文
共 50 条
  • [31] Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
    Hortobagyi, GN
    Theriault, RL
    Porter, L
    Blayney, D
    Lipton, A
    Sinoff, C
    Wheeler, H
    Simeone, JF
    Seaman, J
    Knight, RD
    Heffernan, M
    Reitsma, DJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24): : 1785 - 1791
  • [32] Skeletal complications in cancer patients with bone metastases
    Tsuzuki, Shunsuke
    Park, Sun Hee
    Eber, Matthew R.
    Peters, Christopher M.
    Shiozawa, Yusuke
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (10) : 825 - 832
  • [33] Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
    Body, JJ
    Diel, IJ
    Lichinitser, MR
    Kreuser, ED
    Dornoff, W
    Gorbunova, VA
    Budde, M
    Bergström, B
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1399 - 1405
  • [34] Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
    Westermann, AM
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 537 - 538
  • [35] Atypia in the assessment of breast cancer risk: Implications for management
    Vogel, VG
    DIAGNOSTIC CYTOPATHOLOGY, 2004, 30 (03) : 151 - 157
  • [36] Zoledronic acid reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer
    Kohno, N
    Aogi, K
    Minami, H
    Nakamura, S
    Asaga, T
    Iino, Y
    Watanabe, T
    Goessl, C
    Ohashi, Y
    Takashima, S
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S133 - S133
  • [37] Bone remodeling markers and bone metastases: From cancer research to clinical implications
    Ferreira, Arlindo
    Alho, Irina
    Casimiro, Sandra
    Costa, Luis
    BONEKEY REPORTS, 2015, 4
  • [38] Estrogen and bone Metastases in breast cancer
    Levenson, AS
    Simons, LA
    Thurn, TE
    Satcher, RL
    BONE, 2005, 36 : S243 - S243
  • [39] Mechanisms of bone metastases of breast cancer
    Suva, Larry J.
    Griffin, Robert J.
    Makhoul, Issam
    ENDOCRINE-RELATED CANCER, 2009, 16 (03) : 703 - 713
  • [40] Bone marrow metastases in breast cancer
    Pikarsky, E
    Peretz, T
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (08): : 577 - 578